News | January 04, 2007

French Patent Court Rules Against Abbott’s DES

Jan. 5, 2007 — A French court has ruled that Abbott Laboratories’ Xience V drug-eluting coronary stents infringe patents that are under exclusive worldwide license to Medtronic from evYsio Medical Devices ULC.

AFX News Limited reports that the Tribunal de Grande Instance de Paris ruled that Abbott's Xience V DES infringes evYsio's European Patent No. EP-B- 0 888 093 and has awarded evYsio the right to enjoin the importation, offering for sale, or sale of the Xience V stent in France.

evYsio, a private Canadian company, says the court ruled in its favor in a patent infringement lawsuit it brought against affiliates of Abbott. The injunction is in effect, however, Abbott may appeal the decision.

According to an AFX article, evYsio as well as Medtronic have started infringement lawsuits in other countries alleging that Abbott's MULTI-LINK Vision and/or Xience V coronary stents infringe patents in the U.S., Ireland, the United Kingdom and Germany.


Related Content

News | Stents Drug Eluting

October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on ...

Home October 31, 2023
Home
News | Stents Drug Eluting

October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...

Home October 10, 2023
Home
News | Stents Drug Eluting

July 13, 2023 — Elixir Medical, a developer of breakthrough cardiovascular technologies, announced enrollment completion ...

Home July 13, 2023
Home
News | Stents Drug Eluting

July 12, 2023 — In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study ...

Home July 12, 2023
Home
News | Stents Drug Eluting

May 25, 2023 — First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic ...

Home May 25, 2023
Home
News | Stents Drug Eluting

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent ...

Home January 02, 2023
Home
News | Stents Drug Eluting

December 23, 2022 — According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be ...

Home December 23, 2022
Home
News | Stents Drug Eluting

June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...

Home June 02, 2022
Home
News | Stents Drug Eluting

February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...

Home February 16, 2022
Home
News | Stents Drug Eluting

January 26, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's Synergy Megatron Drug ...

Home January 26, 2021
Home
Subscribe Now